

Reference Manual

Pharmacist Assessment Record (PAR) – General

Patient Name:	Prescription Date:
Patient Address:	
Drug Name/Strength/Dosage:	
Quantity Prescribed:	
Direction for Use:	
Patient's Consent Received: ☐ in writing ☐ verbally	
Rationale for Prescribing:	
□ patient's medication history has been assessed and indicates a chronic stabilized use of the drug	
□ patient is in a life-threatening situation	
□ other	
Other Relevant Patient Information (e.g. drug-related problems, actions plans, patient counselling provided, patient diagnosis): □ Patient's PIP profile reviewed □ Patient's eHR reviewed (if applicable)	
Monitoring and Follow up plan: Patient instructed to call primary care provider's office to make an appointment to review their drug therapy within:	
☐ The next 72 hours ☐ Other (specify details):	
☐ The next week	
Pharmacist to follow up with patient in days to ensure safe and effective use of medication. Follow up completed on Details of follow-up:	
Report any suspected adverse drug reaction or side-effect to MedEffect Canada.	
Name of prescribing pharmacist: Pharmacy contact information:	
Primary care provider notified: ☐ Yes ☐ No circumstance Name: Fax #:	

For SCPP auditing purposes:
☐ Interim Supply (Part K Section 5(1) and 5(2))
☐ Unable to access medications (Part K Section 5(3) and 5(4))
☐ Emergency situation - defined as life threatening (Part K Section 5(5), 5(6) and 5(8))
☐ Insufficient Information (Part K Section 6(1) and 6(2))
☐ Increasing Suitability of a Drug – dosage form change (Part K Section 7(1) and 7(2))
☐ Drug Reconciliation (Part K Section 8(1) and 8(2))
In extraordinary circumstances (must be declared by SCPP): □ Prescribe quantities that exceed limits in the bylaws (Part K Section 10(5)) □ Prescribe when the previous prescription was issued by a pharmacist (Part K Section 10(5)) □ Prescribe when an active patient-practitioner relationship no longer exists (Part K Section 10(5))
Note: This document fulfills the requirements of the Saskatchewan College of Pharmacy Professionals
Regulatory Bylaws Part K Section 2(2).

Revised: October 8, 2020

RELATED RESOURCES

- 1) MedSask Guidelines and PAR that must be used for each specific Minor Ailment and Self-Care condition.
- 2) <u>MedSask Guidelines and Forms</u> that must be used for Vaccine Preventable Diseases and Travel Health.
- 3) PAR CDSA Drugs Maintenance Treatment Extension
- 4) PAR Methadone Maintenance Treatment Extension
- 5) PAR Suboxone Maintenance Treatment Extension
- 6) <u>Summary of Record Keeping Requirements</u> to distinguish between PAR as a 'prescription' and PAR as a 'patient record'